Virtual Library
Start Your Search
I. Goto
Author of
-
+
P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 2
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.07-013 - A Retrospective Analysis of Adjuvant Chemotherapy in Patients with Completely Resected SCLC (ID 1418)
09:30 - 09:30 | Author(s): I. Goto
- Abstract
Background:
Several clinical studies have demonstrated the efficacy and safety of the adjuvant chemotherapy for patients with small cell lung cancer (SCLC) , particularly in patients with stage Ⅰ disease. But it is unclear which chemotherapy regimen is the most efficacious for SCLC patients who underwent surgery, due to the rarity. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for patients with SCLC retrospectively.
Methods:
From January 2002 to September 2014, we retrospectively analyzed the clinical data of 23 patients with SCLC who received surgery in our institute. Seventeen patients received adjuvant chemotherapy. Six patients was observed with no chemotherapy after surgery, due to old age or poor condition（n=4）, patient refusal（n=1）, early post-operative relapse（n=1）.
Results:
The chemotherapy regimens were cisplatin and etoposide（PE）in 8 patients, and carboplatin and etoposide （CE） in 9 patients. Median time from surgery to starting chemothetapy was 1.5 months, and median follow-up time was 39.5 months. 12 pts （70%） received full cycles of chemotherapy. The recurrence was observed in 2 of 8 pts who received PE therapy and 2 of 9 patients who received CE therapy in April 2015. The median recurrence free survival (RFS) of patients who received adjuvant chemotherapy was not reached, and the RFS of patients with no chemotherapy was 7.62 months（Log-rank test P value 0.0007）. No treatment related death was observed.
Conclusion:
The adjuvant chemotherapy for patients with small cell lung cancer may be safe and efficatious.
-
+
P3.07-015 - Final Report of Phase I/II Study of Induction Carboplatin and Irinotecan Followed by TRT for Elderly Patients with LD-SCLC: TORG 0604 (ID 3232)
09:30 - 09:30 | Author(s): I. Goto
- Abstract
Background:
In elderly patients with LD-SCLC, the role of irinotecan has been unclear and the timing of TRT combined with chemo-therapy has not been fully evaluated. Furthermore, no standard treatment has been established for them. We report a phase I/II trial of induction chemotherapy of carboplatin and irinotecan followed by sequential TRT in this population.
Methods:
Patients with untreated, measurable LD-SCLC >70 years with performance status (PS) 0 to 2 and adequate organ function were eligible. Treatment consisted of induction with carboplatin on day 1 and irinotecan on days 1 and 8 every 21 days for four cycles. TRT of 54Gy in 27 fractions was then administered sequentially. Carboplatin dose was escalated from AUC of 4 to 5 (Levels 1 and 2, respectively) with a fixed dose of irinotecan at 50 mg/m[2]. The primary objective of the phase II portion was evaluation of efficacy.
Results:
A total of 41 patients were enrolled [median age 75 years, range 70-86 years; 31 male, 10 female; PS 0/1/2: 22/18/1]. At Level 1 (n=6), one patient experienced dose-limiting toxicity (DLT) as Grade 3 hypertension. At Level 2 (n=6), two patients experienced DLT as Grade 4 thrombocytopenia. Therefore, level 1 was chosen as the recommended dose. The phase II trial was then expanded by 35 patients in the level 1 based on the Simon minimax design. In all cohorts, the median chemotherapy cycle was 4 (1/2/3/4 courses administered as 4/2/2/33); median radiation dose was 54Gy (range 36-60). Toxicities were generally mild, as expected. Gr 3/4 leukopenia and thrombocytopenia were both observed in six (15%) patients. No Gr 3/4 diarrhea or esophagitis was noted. Although Gr 3 febrile neutropenia and Gr 3 pneumonitis were seen in two patients each, no treatment-related deaths occurred. There were five complete responses and 32 partial responses, for a response rate of 90%. With median follow-up of 80.4 months (n=41), median progression-free and overall survival times were 11.2 and 27.1 months, respectively.
Conclusion:
Induction chemotherapy with carboplatin plus irinotecan followed by sequential TRT was well tolerated and highly effective in elderly patients with LD-SCLC. Further confirmatory studies are warranted.
